Tissue-type plasminogen activator is a multiligand cross-β structure receptor

Current Biology

Volumn 12, Issue 21, 2002, Pages 1833-1839

  Kranenburg, Onno ^a   Bouma, Barend ^a   Kroon Batenburg, Loes M J ^b   Reijerkerk, Arie ^a   Wu, Ya Ping ^a   Voest, Emile E ^a   Gebbink, Martijn F B G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION;

PROTEIN CONFORMATION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037195269     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(02)01224-1     Document Type: Article

References (26)

1. Nieuwenhuizen, W. (2001). Fibrin-mediated plasminogen activation. Ann. N Y Acad. Sci. 936, 237-246.
2. Selkoe, D.J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
3. Kingston, I.B., Castro, M.J., and Anderson, S. (1995). In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat. Med. 1, 138-142.
4. Wnendt, S., Wetzels, I., and Gunzler, W.A. (1997). Amyloid beta peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb. Res. 85, 217-224.
5. Van Nostrand, W.E., and Porter, M. (1999). Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38, 11570-11576.
6. Lansbury, P.T., Jr. (1992). In pursuit of the molecular structure of amyloid plaque: New technology provides unexpected and critical information. Biochemistry 31, 6865-6870.
7. Hoppener, J.W., Ahren, B., and Lips, C.J. (2000). Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343, 411-419.
8. Elghetany, M.T., and Saleem, A. (1988). Methods for staining amyloid in tissues: A review. Stain Technol. 63, 201-212.
9. Serpell, L.C., Fraser, P.E., and Sunde, M. (1999). X-ray fiber diffraction of amyloid fibrils. Methods Enzymol. 309, 526-536.
10. Rochet, J.C., and Lansbury, P.T., Jr. (2000). Amyloid fibrillogenesis: Themes and variations. Curr. Opin. Struct. Biol. 10, 60-68.
11. Nilsson, M.R., Nguyen, L.L., and Raleigh, D.P. (2001). Synthesis and purification of amyloidogenic peptides. Anal. Biochem. 288, 76-82.
12. Goldsbury, C., Goldie, K., Pellaud, J., Seelig, J., Frey, P., Muller, S.A., Kistler, J., Cooper, G.J., and Aebi, U. (2000). Amyloid fibril formation from full-length and fragments of amylin. J. Struct. Biol. 130, 352-362.
13. Jaikaran, E.T., Higham, C.E., Serpell, L.C., Zurdo, J., Gross, M., Clark, A., and Fraser, P.E. (2001). Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308, 515-525.
14. Westermark, P., Engstrom, U., Johnson, K.H., Westermark, G.T., and Betsholtz, C. (1990). Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87, 5036-5040.
15. Hudry-Clergeon, G., Freyssinet, J.M., Torbet, J., and Marx, J. (1983). Orientation of fibrin in strong magnetic fields. Ann. N Y Acad. Sci. 408, 380-387.
16. Lendrum, A.C., Slidders, W., and Fraser, D.S. (1972). Renal hyalin. A study of amyloidosis and diabetic fibrinous vasculosis with new staining methods. J. Clin. Pathol. 25, 373-396.
17. Ku, C.S., and Fiedel, B.A. (1983). Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin. J. Exp. Med. 158, 767-780.
18. Merkle, D.L., Cheng, C.H., Castellino, F.J., and Chibber, B.A. (1996). Modulation of fibrin assembly and polymerization by the beta-amyloid of Alzheimer's disease. Blood Coagul. Fibrinolysis 7, 650-658.
19. Meyer, K., Smith, R., and Williams, E.C. (1987). Inhibition of fibrin polymerization by serum amyloid P component and heparin. Thromb. Haemost. 57, 345-348.
20. Machovich, R., and Owen, W.G. (1997). Denatured proteins as cofactors for plasminogen activation. Arch. Biochem. Biophys. 344, 343-349.
21. Radcliffe, R., and Heinze, T. (1981). Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: A possible additional role for plasminogen activator? Arch. Biochem. Biophys. 211, 750-761.
22. Tucker, H.M., Kihiko, M., Caldwell, J.N., Wright, S., Kawarabayashi, T., Price, D., Walker, D., Scheff, S., McGillis, J.P., Rydel, R.E., et al. (2000). The plasmin system is induced by and degrades amyloid-beta aggregates. J. Neurosci. 20, 3937-3946.
23. Tucker, H.M., Kihiko-Ehmann, M., Wright, S., Rydel, R.E., and Estus, S. (2000). Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J. Neurochem. 75, 2172-2177.
24. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C.M., and Stefani, M. (2002). Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
25. Chen, Z.L., and Strickland, S. (1997). Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91, 917-925.
26. Tsirka, S.E., Gualandris, A., Amaral, D.G., and Strickland, S. (1995). Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377, 340-344.